TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence
Isabel Puig(Institut Curie), Héctor G. Pálmer(CIBBIM-Nanomedicine), Lorena Ramírez(Vall d'Hebron Hospital Universitari), Stephan P. Tenbaum(CIBBIM-Nanomedicine), Juan A. Recio(Vall d'Hebron Institut de Recerca), Josep Tabernero(Deaconess Hospital), Luigi Terracciano(Humanitas University), Ginevra Caratù(Cancer Genomics Centre), Oriol Arqués(CIBBIM-Nanomedicine), Cristina Eguizábal(BioCruces Health research Institute), Jordi Martínez‐Quintanilla(Vall d'Hebron Institute of Oncology), Irene Chicote(CIBBIM-Nanomedicine), Estefania Cuesta-Borràs(CIBBIM-Nanomedicine), Oriol Casanovas(Institut Català d'Oncologia), Guillem Argilés(Vall d'Hebron Hospital Universitari), Joan Seoane(Institució Catalana de Recerca i Estudis Avançats), Pilar Gonzalo(Instituto de Salud Carlos III), Ana Vivancos(Vall d'Hebron Institute of Oncology), Violeta Serra(Vall d'Hebron Institute of Oncology), Stefania Landolfi(Universitat Autònoma de Barcelona), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Rodrigo Dienstmann(Universitat de Vic - Universitat Central de Catalunya), Atenea Soto(Universitat Autònoma de Barcelona), Aleix Prat(Hospital Clínic de Barcelona), Alicia G. Arroyo(Universidad Complutense de Madrid), Susana Aguilar(Institut d'Investigació Biomédica de Bellvitge), Alberto Villanueva(Institut d'Investigació Biomédica de Bellvitge)
Cited by 108
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
|Cancer Cell|2009|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k